OXFORD BIODYNAMICS PLC (LON:OBD)
SECTOR – HEALTHCARE
MARKET CAP – £209m
CURRENT PRICE – 242p#
Prospective study data presented at ALS disease conference
Oxford BioDynamics presented prospective study data regarding its proprietary EpiSwitch™ technology at the 2017 Annual Northeast ALS Consortium (NEALS) Meeting in Florida.
The prospective study measured the sensitivity and specificity of two epigenetic-based Amyotrophic Lateral Sclerosis (ALS) disease signatures and how they may assist in the diagnosis of ALS and the prognosis of fast versus slow progressing ALS.
ALS is a progressive neurodegenerative disease, affecting nerve cells in the brain and spinal cord. There is currently no cure. 100 patients underwent clinical assessments and provided blood samples which were analyzed using the Company’s EpiSwitch™ technology.
Comparisons between healthy volunteers and ALS patients revealed two ALS-related epigenetic signatures, with one signature having diagnostic potential whilst the other may aid prediction of prognosis.
The diagnostic epigenetic signature had specificity of 75% and sensitivity of 88% whilst the prognostic test had specificity and sensitivity of 80%.
Dr Alexandre Akoulitchev, Chief Scientific Officer of Oxford BioDynamics, commented: “This prospective study has delivered two new and unique epigenetic biomarker signatures that have the potential to improve the time to diagnosis and provide a predictive prognosis for the progression of the disease. We look forward to further expanding our EpiSwitchTM ALS studies in close collaboration with leading clinical experts, both in US and UK.”
Oxford BioDynamics is a clinical stage biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture for use within the pharmaceutical and biotechnology industry.
VELTYCO GROUP (LON:VLTY)
SECTOR – LEISURE
RATING – BUY*
MARKET CAP – £65.4m
CURRENT PRICE – 88p#
TARGET PRICE – 110p
Esports.com partnership, accessing a US$500m online gaming market
Veltyco Group has entered into a partnership agreement with Esports Radar Ltd., a newly-incorporated company in Malta focused to develop esports-based opportunities. Esports Radar has established a wholly-owned subsidiary, Esports.com Ltd., to tap the potential of gaming based on the rapidly-developing enthusiasm for esports. It owns the domain name www.esports.com.
Esport competition has developed around Playstation-, Xbox- and PC-based gaming. Esports.com aims to build an online community to produce content aimed at esports enthusiasts. This will include esports merchandise, hardware or in-game items, licensed esports betting and user guides, tutorials and coaching.
Veltyco has taken a minority interest in Esports for a nominal consideration, and will use its Bet90 brand as the platform for the partnership and marketing its gaming products.
Veltyco recently reported strong interims – revenue +202% at €6.4m, EBITDA +410% at €3.8m – and is clearly aware of new opportunities such as the esports online gaming trend. 2017 global esports revenue is estimated at US$465m (source; gamesindustry.biz) backed by some 385m gamers and augmented by popular international tournaments, in 2015 the establishment of the first dedicated esports arena in Santa Ana and a major new venue planned at the Luxor in Las Vegas for 2018.
Veltyco is a marketing and promotions business which refers customers to online casino, sports betting, lotteries and options trading brands.